VP, Gene Editing Programs - Hemophilia A (BLA Prep)

Scorpion Therapeutics; Emeryville (CA); On-site; USD 250,000 - 360,000; Full time

Job summary

Scorpion Therapeutics in Emeryville, CA seeks a Vice President and Program Lead for MGX-001 to drive clinical development from Phase 1/2 to BLA filing in gene editing for hemophilia A.

You will define and execute development strategy, lead cross‑functional teams across clinical, regulatory, CMC and manufacturing, manage integrated timelines and budgets, oversee regulatory interactions (IND/BLA), ensure GxP compliance and report progress to executives and the Board.

Qualifications

• Advanced degree required.
• 15+ years in biopharma with drug development leadership.
• Familiarity with GCP, GMP, CMC and ICH guidelines.

Responsibilities

• Define and execute the development strategy.
• Lead cross-functional teams including clinical, regulatory, CMC and manufacturing; develop integrated timelines and budgets.
• Manage regulatory interactions (IND, BLA, international filings) and communicate progress to executives and the Board.

Skills

Cross-functional leadership

Regulatory strategy

Program management

GxP compliance

IND/BLA filings

Education

Advanced degree

Job description

Scorpion Therapeutics in Emeryville, CA seeks a Vice President and Program Lead for MGX-001 to drive clinical development from Phase 1/2 to BLA filing in gene editing for hemophilia A.

You will define and execute development strategy, lead cross‑functional teams across clinical, regulatory, CMC and manufacturing, manage integrated timelines and budgets, oversee regulatory interactions (IND/BLA), ensure GxP compliance and report progress to executives and the Board.